Table 4.
Treatment efficacy of entecavir in chronic hepatitis B
| Ref. | No. of patients | HBeAg | Therapy regimen | HBeAg loss (%)/seroconversion from HBeAg to anti-HBe (%) | Undetectable of HBV DNA (%) | Normalization of ALT (%) | HBsAg loss (n) |
| 1Chang et al[66] | 354 NUCs - treatment-naive | Positive | ETV 0.5 mg daily for 48 wk | 22/21 | 67 | 68 | 6 |
| 355 NUCs - treatment-naive | Positive | LAM 100 mg daily for 48 wk | 20/18 | 36 | 60 | 4 | |
| 2Gish et al[67] | 243 NUCs - treatment-naive | Positive | ETV 0.5 mg daily for 2 yr | NA/31 | 80 | 87 | 18 |
| 164 NUCs - treatment-naive | Positive | LAM 100 mg daily for 2 yr | NA/26 | 39 | 79 | 10 | |
| 1Lai et al[70] | 296 | Negative | ETV 0.5 mg daily for 48 wk | NA/NA | 90 | 78 | 1 |
| 287 | Negative | LAM 100 mg daily for 48 wk | NA/NA | 72 | 71 | 1 |
Treatment efficacies were assessed at 48 wk1, or 2 years2. ETV: Entecavir; NUCs: Nucleos(t)ide analogues; NA: Not available; LAM: Lamivudine; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis B surface antigen; Anti-HBe: Antibody to HBe antigen.